All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
ASPEN: 5.8-year follow-up of zanubrutinib in patients with WM
|
Zanubrutinib is a covalent BTK inhibitor that has been approved for adult patients with WM by the EMA and the FDA. ASPEN (NCT03053440) is a phase III, open-label trial of zanubrutinib vs ibrutinib in patients with WM.1 Full details of the study design were previously summarized on the Lymphoma Hub. LTE1, a long-term extension phase, enrolled 75 patients with WM treated with zanubrutinib in the APSEN trial.1 Results were presented at the 66th ASH Annual Meeting and Exposition by D’Sa.1 |
| Key learnings |
| At a median follow-up of 5.8 years, the ORR was 96.1% in MYD88mut patients and 84.6% MYD88WT in patients. |
| The median DoR was 55.7 months and 41.1 months in MYD88mut and MYD88WT patients, respectively. The 60-month event-free PFS rate was 74.8% and 39.3% in MYD88mut and MYD88WTpatients, respectively. |
| Grade ≥3 TEAEs occurred in 29.2% of patients, with serious TEAEs in 23.6% of patients. |
| Long-term data from the ASPEN trial demonstrate deep and durable efficacy and tolerable safety profile of zanubrutinib regardless of mutation status, supporting its use in patients with WM. |
Abbreviations: BTK, Bruton’s tyrosine kinase inhibitor; DoR, duration of response; EMA, European Medical Agency; FDA, U.S. Food and Drug Administration; LTE1, long-term extension; ORR, overall response rate; PFS, progression-free survival; mut, mutated; TEAE, treatment-emergent adverse event; WM, Waldenstrom’s macroglobulinemia; WT, wild type.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?
